Dexamethasone SR is under clinical development by Thea Open Innovation SASU and currently in Phase II for Retinal Vein Occlusion. According to GlobalData, Phase II drugs for Retinal Vein Occlusion have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dexamethasone SR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dexamethasone SR overview

Dexamethasone is under development for the treatment of posterior inflammatory eye diseases including diabetic macular edema, retinal vein occlusion, retinitis pigmentosa, cystoid macular edema and non-infectious uveitis. It is administered through the intravitreal route as an implant. It is developed based on epidel technology. The drug candidate targets the glucocorticoid receptor. The IBE-814 IVT  Implant (dexamethasone) releases a low, consistent and efficacious dose of dexamethasone for delivery through a 30-gauge needle over a period of 6 months. It is an sustained release formulation.

Thea Open Innovation SASU overview

Thea Open Innovation SASU is a biotechnology company that aim is to identify, evaluate and support the most innovative developments in eye care, throughout licensing agreements and/or equity investments. The company is headquartered in Clermont Ferrand, A

For a complete picture of Dexamethasone SR’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.